Distinct mutational landscape of inverted urothelial papilloma

J Pathol. 2019 Sep;249(1):3-5. doi: 10.1002/path.5307. Epub 2019 Jul 2.

Abstract

A recent study has identified gene mutations involving the MAPK/ERK pathway, particularly the HRAS gene, in all inverted urothelial papillomas (IUPs), in the absence of pathway mutations in TERT promoter, FGFR3, and TP53/RB1genes. Neither recurrence nor progression was observed in IUPs. These data support several longstanding hypotheses: (1) IUPs are benign and do not recur or progress; (2) they harbor mutations that are different from those of urothelial carcinoma; and (3) they arise through different molecular mechanisms than low- or high-grade urothelial carcinoma. As the most critical differential diagnosis in this context is inverted-type urothelial carcinoma, more comprehensive studies are needed to compare and contrast these entities. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Keywords: FGFR3; MAPK/ERK pathway; TERT promoter mutation; inverted urothelial papilloma; molecular genetics; urinary bladder.

Publication types

  • Comment

MeSH terms

  • Genomics
  • Humans
  • Mutation
  • Neoplasm Recurrence, Local*
  • United Kingdom
  • Urinary Bladder Neoplasms*